Giant Cell Tumor of the Distal Humerus: A Rare Location With a Good Response to Denosumab.
AI interpretation is pending for this paper.
Open original publication →What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Giant cell tumors (GCTs) are rare, benign, locally aggressive neoplasms. They typically affect the metaphyseal region; their occurrence at the distal humerus is rare, making their management challenging. We report the case of a 13-year-old girl, skeletally immature, admitted for a painful, progressive mass at her right elbow (circumference 26 cm) with functional limitation. Radiological evaluation by magnetic resonance imaging (MRI revealed a large osteolytic epiphysometaphyseal lesion of the right distal humerus, centered on the medial epicondyle and measuring 36 × 35 × 60 mm, with cortical rupture and soft-tissue invasion (Campanacci grade III). The bone biopsy revealed a GCT with no signs of malignancy. The staging workup was negative. Given the complex joint location and the patient's young age, the multidisciplinary team decided to initiate anti-receptor activator of nuclear factor-κB ligand (RANKL) therapy with denosumab (70 mg/m² subcutaneously (SC)) on days 1, 8, 15, and 28, followed by monthly administration, along with calcium and vitamin D supplementation. The seven-month follow-up was favorable: regression of the swelling (circumference 20 cm), complete joint release, and lesion stability on the follow-up MRI, with no calcium-phosphate complications. Denosumab is used in situations where surgery is not an option to reduce tumor size and control its progression. Its use increases the risk of calcium-phosphorus abnormalities and growth disorders. Our case demonstrated that a well-defined treatment regimen combined with calcium-phosphorus supplementation could control the aggressiveness of GCTs.